PARP1 and germ cell tumor: Additionally, the cytostatic potential of cisplatin was not hampered in two germ cell tumor lines, making PARP an attractive target for an adjuvant therapy aimed at limiting the negative ototoxic side-effects of cisplatin anti-cancer treatments.